Gobbo, F.; Martelli, F.; Di Virgilio, A.; Demaria, E.; Sarli, G.; Migliaccio, A.R.
The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination. Int. J. Mol. Sci. 2024, 25, 7703.
https://doi.org/10.3390/ijms25147703
AMA Style
Gobbo F, Martelli F, Di Virgilio A, Demaria E, Sarli G, Migliaccio AR.
The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination. International Journal of Molecular Sciences. 2024; 25(14):7703.
https://doi.org/10.3390/ijms25147703
Chicago/Turabian Style
Gobbo, Francesca, Fabrizio Martelli, Antonio Di Virgilio, Elena Demaria, Giuseppe Sarli, and Anna Rita Migliaccio.
2024. "The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination" International Journal of Molecular Sciences 25, no. 14: 7703.
https://doi.org/10.3390/ijms25147703
APA Style
Gobbo, F., Martelli, F., Di Virgilio, A., Demaria, E., Sarli, G., & Migliaccio, A. R.
(2024). The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination. International Journal of Molecular Sciences, 25(14), 7703.
https://doi.org/10.3390/ijms25147703
